ADAPT

Platform Trial for the Evaluation of Antimicrobials for the Treatment of Multiple Resistant Bacterial Pathogens in Bacteremia

An innovative initiative to design and simulate a clinical platform trial that is customized to efficiently evaluate multiple experimental antimicrobial therapies for the treatment of multiple categories of infections (HAP/VAP, UTI and IA) due to MDR bacterial pathogens. The team consists of statisticians and clinicians from Berry Consultants, ARLG, GSK, Roche, AstraZeneca, The Medicines Company, JHU, BARDA, Sanofi, and the FDA.

http://www.berryconsultants.com/antibiotic-platform-design/